Successful treatment of membranoproliferative glomerulonephritis associated with hepatitis B and C virus simultaneous infection patient.
A
A
Mima
N
N
Iehara
T
T
Matsubara
S
S
Yamamoto
H
H
Abe
K
K
Nagai
M
M
Matsuura
T
T
Murakami
S
S
Kishi
T
T
Araoka
F
F
Kishi
N
N
Kondo
R
R
Shigeta
K
K
Yoshikawa
T
T
Takahashi
T
T
Kita
T
T
Doi
A
A
Fukatsu
D000998:Antiviral Agents / Q000627:therapeutic use*; D001706:Biopsy; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D015432:Glomerulonephritis, Membranoproliferative / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D016174:Hepacivirus / Q000235:genetics; D006509:Hepatitis B / Q000150:complications* / Q000175:diagnosis / Q000821:virology; D006515:Hepatitis B virus / Q000235:genetics; D006526:Hepatitis C / Q000150:complications* / Q000175:diagnosis / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008856:Microscopy, Fluorescence; D008875:Middle Aged; D012367:RNA, Viral / Q000032:analysis; D012254:Ribavirin / Q000627:therapeutic use*
D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D012254:Ribavirin